BRIEF published on 06/16/2026 at 21:21, 4 days 14 hours ago Medincell: Key Results and Initiatives for 2025-2026 Innovation Treasury R&D Royalties Medincell
BRIEF published on 05/21/2026 at 19:29, 30 days 15 hours ago EMA Accepts Teva's Application for Long-Acting Schizophrenia Treatment Schizophrenia Treatment Teva Pharmaceuticals EMA Approval Olanzapine Injectable Long-acting Formulation
PRESS RELEASE published on 05/21/2026 at 19:24, 30 days 15 hours ago Inside Information / Other news releases European Medicines Agency accepts Teva's Marketing Authorization Application for Olanzapine Long-Acting Injectable to treat schizophrenia in adults. Teva and Medincell announce EMA acceptance for innovative treatment option Schizophrenia Medincell Olanzapine Teva EMA
BRIEF published on 04/29/2026 at 13:44, 1 month 21 days ago Impressive sales growth for UZEDY® in Q1 2026 Schizophrenia Medincell Teva Pharmaceuticals UZEDY® Q1 2026 Sales
BRIEF published on 04/29/2026 at 13:44, 1 month 21 days ago UZEDY® Q1 2026 Sales Surge by 62% FDA Approvals Olanzapine LAI UZEDY® Sales Teva Partnership Medincell Growth
PRESS RELEASE published on 04/29/2026 at 13:39, 1 month 21 days ago Inside Information / Other news releases Medincell's partner Teva Pharmaceuticals reports UZEDY Q1 2026 net sales of $63M, a 62% increase year-on-year. Olanzapine LAI NDA accepted by FDA. Medincell focuses on long-acting injectable treatments across various therapeutic areas Medincell Teva Pharmaceuticals Olanzapine LAI UZEDY Long-acting Injectable
BRIEF published on 04/20/2026 at 11:18, 2 months 1 day ago BNP Paribas Développement crosses a threshold at MEDICELL Euronext Paris Voting Rights BNP Paribas Threshold Crossing MEDICELL
BRIEF published on 04/02/2026 at 19:05, 2 months 18 days ago Medincell: Update on capital and voting rights Share Capital Voting Rights Shares Euronext AMF
BRIEF published on 02/20/2026 at 21:42, 4 months ago Teva's Olanzapine Injectable Suspension Gains FDA Nod Schizophrenia Olanzapine Teva Pharmaceuticals FDA Acceptance Long-acting Injectable
PRESS RELEASE published on 02/20/2026 at 21:37, 4 months ago Inside Information / Other news releases FDA accepts Teva's NDA for once-monthly olanzapine for schizophrenia treatment, addressing treatment gap. Teva and Medincell collaborate for innovative solution FDA Schizophrenia Medincell Olanzapine Teva
Published on 06/20/2026 at 01:00, 1 day 10 hours ago Onco-Innovations Announces Non-Brokered LIFE Offering
Published on 06/20/2026 at 00:00, 1 day 11 hours ago Onco-Innovations Reports Completion of 300g Active Pharmaceutical Ingredient for ONC010 Scale-Up Supporting IND-Enabling Development
Published on 06/19/2026 at 04:30, 2 days 6 hours ago Uraniumx Discovery Corp. Announces Acquisition of Common Shares of Gold'n Futures Mineral Corp
Published on 06/19/2026 at 01:20, 2 days 10 hours ago American Hotel Income Properties REIT LP Reports Voting Results of Annual and Special Meeting
Published on 06/19/2026 at 01:07, 2 days 10 hours ago Usha Resources Announces Share Issuance in Payment of Debenture Interest, Adopts Semi-Annual Reporting
Published on 06/20/2026 at 21:25, 13 hours 55 minutes ago VIVATECH 2026 CELEBRATES ITS 10TH ANNIVERSARY WITH A RECORD EDITION SURPASSING 200,000 VISITORS
Published on 06/20/2026 at 06:00, 1 day 5 hours ago Successful debut of International Symposium on Emergency Response and Aeromedical Services in Hong Kong
Published on 06/19/2026 at 20:17, 1 day 15 hours ago 2CRSi SA: 2CRSi Responds Point-by-Point to the Grizzly Research Report and Reaffirms the Reality of Its Business Operations
Published on 06/19/2026 at 19:01, 1 day 16 hours ago Fuller, Smith & Turner PLC: Publication of the Annual Report and Accounts for the 52 weeks ending 28 March 2026 and Notice of 2026 Annual General Meeting
Published on 06/19/2026 at 19:33, 1 day 15 hours ago Disclosure of transactions in own shares from June 15 to June 19, 2026
Published on 06/19/2026 at 19:23, 1 day 15 hours ago Imerys-06-2026-information-share-capital-and-voting-rights-as-of-31-May-2026
Published on 06/18/2026 at 18:00, 2 days 17 hours ago Outstanding shares and voting rights statement at 31 May 2026
Published on 06/18/2026 at 17:45, 2 days 17 hours ago EURAZEO INVESTS IN LAURALU, A PAN-EUROPEAN PROVIDER OF DEPLOYABLE INDUSTRIAL INFRASTRUCTURE
Published on 06/18/2026 at 17:38, 2 days 17 hours ago Statement of transactions in own shares from June 8, 2026 to June 12, 2026
